ATYR PHARMA INC (LIFE) Stock News
NASDAQ:LIFE - Nasdaq - US0021202025 - Common Stock - Currency: USD
LIFE Latest News, Press Relases and Analysis
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” ...
Mentions: ATYR
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Ticker symbol change to take effect on Wednesday, June 5, 2024
Mentions: ATYR
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips aTyr Pharma (NASDAQ:LIFE) just reported results for the first quarter of 2024.a...
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference...
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
Findings further demonstrate that NRP2 is an important new immune target in ILD and that efzofitimod modulates myeloid cells to confer anti-inflammatory benefit
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis...
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma to Participate in April Investor Conferences...
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips aTyr Pharma (NASDAQ:LIFE) just reported results for the fourth quarter of 2023....
aTyr Pharma to Present at Upcoming Investor Conferences
LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024
LIFE stock results show that aTyr Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
aTyr Pharma announces first quarter 2024 results and provides corporate update ...
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023
LIFE stock results show that aTyr Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
aTyr Pharma to Participate in April Investor Conferences
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while.
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update ...
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results...
The 3 Best Penny Stocks to Buy in February 2024
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.
aTyr Pharma to Present at November Investor Conferences
aTyr Pharma announces that it will present at two investor conferences in November 2023....
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants...
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease...
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
Dr. Frederick to advise Company on corporate affairs and commercial strategy for efzofitimod in interstitial lung disease (ILD).
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models....
aTyr Pharma files for $300M mixed-shelf offering (NASDAQ:LIFE)
Read about aTyr Pharma's $300M mixed-shelf offering and potential securities issuance, but note that the prospectus is not an offer to sell.
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™...
aTyr Pharma to Present at November Investor Conferences
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
Multiple centers in the U.S. are open for enrollment